DxS enters Scorpions deal with SIRS-Lab
This article was originally published in Clinica
Executive Summary
Manchester, UK-based molecular diagnostics firm DxS has licensed its Scorpions real-time PCR technology to German sepsis specialist SIRS-Lab for an undisclosed fee. The EU-wide agreement allows SIRS-Lab to incorporate DxS’ technology into its Siqnature sepsis prediction and monitoring test, which it aims to make commercially available in 2009. The Siqnature allows the early detection of sepsis by differentiating between infectious and non-infectious states in patients – the test is based on proprietary transcriptomic biomarkers that indicate sepsis earlier and more reliably than currently possible, claims Jena-based SIRS-Lab. The deal between the two firms also includes an option for worldwide IVD utilisation of the Scorpions technology.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals